Drug Prices
AHA statement before the Senate Committee on Health, Education, Labor and Pensions on Reducing Health Care Costs: Eliminating Excess Health Care Spending and Improving Quality and Value for Patients.鈥
The AHA today submitted comments on the Department of Health and Human Services鈥 blueprint to lower drug prices and out-of-pocket costs.
AHA comments on the Department of Health and Human Services鈥 Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
The AHA appreciates the Medicare Payment Advisory Commission鈥檚 concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing.
On behalf of our nearly 5,000 member hospitals, health systems and other health care organizations, including more than 1,900 hospitals that participate in the 340B drug savings program, and our clinician partners 鈥 including more than 270,000 affiliated physicians, 2 million nurses and other鈥
The 340B drug savings program must be reformed, Health and Human Services Secretary Alex Azar said today at a 340B conference in Washington, D.C.
The Health, Education, Labor and Pensions Committee today held the first in a series of hearings on how to reduce health care costs, which will examine administrative costs and waste, how to improve transparency, private sector solutions and other issues.
The Senate Finance Committee today held a hearing on strategies to reduce prescription drug costs and encourage innovation and competition in the market.
AHA statement before the Senate Finance Committee on Prescription Drug Affordability and Innovation: Addressing Challenges in Today鈥檚 Market.
AHA Statement before the Senate Committee on Health, Education, Labor and Pensions regarding 鈥淓ffective Administration of the 340B Drug Pricing Program.鈥